Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness and Safety of Orforglipron for Weight Management in Adolescents with Obesity or Overweight

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for adolescents who have been diagnosed with obesity or are overweight with related health issues. The treatment being tested is called Orforglipron (also known by its code name LY3502970), which is taken as a capsule by mouth. The purpose of the study is to see if Orforglipron can help reduce body weight more effectively than a placebo.

Participants in the study will be randomly assigned to receive either Orforglipron or a placebo. The study will last for a period of time, during which participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their body weight. The main goal is to observe the percent change in Body Mass Index (BMI) from the start of the study to the end.

This trial aims to provide valuable information on the safety and effectiveness of Orforglipron in managing weight in young people with obesity or overweight conditions. The study is designed to ensure the well-being of participants while gathering important data that could lead to new treatment options for weight management in adolescents.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants are confirmed to have obesity or overweight with at least one related health issue, such as high blood pressure or type 2 diabetes.

    Participants have previously been unable to lose weight through diet and exercise alone.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to establish a baseline for the participant's Body Mass Index (BMI).

    This baseline will be used to measure changes over the course of the study.

  3. Step 3

    Medication administration

    Participants are randomly assigned to receive either the study medication, orforglipron, or a placebo.

    The medication is taken orally in the form of a capsule once daily.

  4. Step 4

    Ongoing monitoring

    Participants are monitored regularly to assess the efficacy and safety of the treatment.

    Regular check-ins include measuring changes in BMI and monitoring for any side effects.

  5. Step 5

    Completion of study

    The study is designed to last until December 15, 2026.

    The primary goal is to observe the percent change in BMI from the start of the study to week 72.

Who can join the trial?

10 criteria

  • Must have been diagnosed with **obesity** or **overweight**. This means having a higher body weight than what is considered healthy for a certain height.
  • Must have at least one weight-related **comorbidity**. This is a medical condition that occurs along with obesity or overweight, such as:
    • Abnormal **lipids**: This refers to having unhealthy levels of fats in the blood.
    • High **blood pressure**: This is when the force of the blood against the artery walls is too high.
    • **Fatty liver disease**: This is a condition where fat builds up in the liver.
    • **Sleep apnea**: This is a sleep disorder where breathing repeatedly stops and starts.
    • **Prediabetes**: This is a condition where blood sugar levels are higher than normal but not high enough to be considered diabetes.
    • Type 2 **diabetes**: This is a condition that affects the way the body processes blood sugar.
    • Must have tried to lose weight with a healthy diet and physical activity but have not been successful.
    • Both **men** and **women** can participate.
    • Participants must be within the specified age range for the study.

Who cannot join the trial?

5 criteria

  • Individuals who are not within the specified age range for the study.
  • Individuals who do not have a **BMI** (Body Mass Index) that qualifies them as **obese** or **overweight**.
  • Individuals who are part of a vulnerable population that the study is not designed to include.
  • Individuals who have medical conditions or are taking medications that could interfere with the study results.
  • Individuals who are unable to comply with the study procedures or follow-up requirements.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Orforglipron: This medication is being tested to see if it can help reduce body mass index (BMI) in adolescents who are either obese or overweight with related health issues. It is taken orally once a day and is being compared to a placebo to determine its effectiveness and safety in managing weight.

What is already known about the treatment

Orforglipron – This medication is administered orally in the form of a tablet. It is currently being studied in clinical trials for its effectiveness and safety in managing chronic weight issues in adolescents with obesity or overweight conditions. The main therapeutic use of Orforglipron is to aid in weight reduction by lowering the Body Mass Index (BMI). It works by mimicking the action of a hormone that regulates appetite and food intake, helping to reduce hunger and promote a feeling of fullness. Orforglipron is classified as a GLP-1 receptor agonist, a type of drug that influences the body's natural processes to control weight.

Investigated diseases

  • Obesity

    A condition characterized by excessive body fat accumulation that may negatively impact health. It develops when calorie intake exceeds the amount of calories burned, leading to weight gain. Over time, this can result in increased body mass index (BMI) and may affect physical mobility and energy levels. Obesity is often associated with lifestyle factors such as diet and physical activity, but genetics can also play a role. It can lead to various health issues, including joint problems and fatigue.

  • Overweight

    A condition where an individual has more body weight than is considered healthy for their height. It occurs when there is an imbalance between calories consumed and calories expended. This condition can gradually develop due to poor dietary habits and lack of physical activity. Being overweight can lead to increased BMI and may cause discomfort or reduced physical endurance. It is often a precursor to obesity if not managed appropriately.

Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IIITrial ID2024-514081-40-00Protocol codeJAM-MC-PWMP, -PW01Estimated enrolment125 patientsSponsorEli Lilly & Co.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.